Although the PAM50 molecular classification has been instrumental in guiding treatment decisions across various breast cancer subtypes.43,44 It is limited in its ability to capture the full molecular heterogeneity of HR+/HER2+ breast cancer. This evidence concerns the gene HR and breast cancer.